Across TCGA pan-cancer cohorts, MIRLET7A2 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated MIRLET7A2 data layer compared with 10 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MIRLET7A2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MIRLET7A2 expression acts as an unfavorable survival marker.

LUAD are the cancer types where MIRLET7A2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.057	0.812	<.001	36	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: MIRLET7A2 tumor-vs-normal RNA expression · all MIRLET7A2 data types